Skip to main content
SpringerLink
Log in

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

A Guide to Its Use as a Single-Dose Booster Immunization Against Pertussis

  • Adis Drug Clinical Q&A
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Di Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prev Med Hyg. 2005;46(1):33–41.

    Google Scholar 

  2. Halperin SA, Scheifele D, De Serres G, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012;30(5):974–82.

    Article  PubMed  CAS  Google Scholar 

  3. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385–400.

    Google Scholar 

  4. McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its use as a single-dose booster immunization. Drugs. 2012;72(13):1765–91.

    Article  PubMed  CAS  Google Scholar 

  5. Center for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with infants aged <12 months: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(11):1424–6.

    Google Scholar 

  6. Health Protection Agency: HPA guidelines for the public health management of pertussis (online). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287142671506. Accessed 2 Nov 2012.

  7. Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed): US prescribing information. Research Triangle Park (SC): GlaxoSmithKline;2012.

  8. Boostrix suspension for injection (diphtheria, tetanus and pertussis [acellular, component] vaccine [adsorbed, reduced antigen(s) content]): summary of product characteristics. London: European Medicines Agency;2012.

  9. Zhu F, Zhang S, Hou Q, et al. Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™). Hum Vaccin. 2010;6(3):263–9.

    Article  CAS  Google Scholar 

  10. Huang LM, Chang LY, Tang H, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health. 2005;37(6):517.e1–5.

    Article  Google Scholar 

  11. Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine. 2003;21(27–30):4194–200.

    Article  PubMed  CAS  Google Scholar 

  12. Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children [abstract no. 281.00 plus poster]. In: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases, 9–11 Apr 2003, Taormina, Italy.

  13. Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084–93.

    Article  PubMed  Google Scholar 

  14. Theeten H, Van Damme P, Hoppenbrouwers K, et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine. 2005;23(12):1515–21.

    Article  PubMed  CAS  Google Scholar 

  15. Abarca K, Valdivieso F, Potin M, et al. Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults [in Spanish]. Rev Med Chil. 2002;130(5):502–10.

    PubMed  Google Scholar 

  16. Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine. 2006;24(12):2043–8.

    Article  PubMed  CAS  Google Scholar 

  17. Southern J, Andrews N, Burrage M, et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23(29):3829–35.

    Article  PubMed  CAS  Google Scholar 

  18. Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999; 104(6):e70.

    Google Scholar 

  19. Booy R, Van Der Meeren O, Ng SP, et al. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine. 2010;29(1):45–50.

    Article  PubMed  CAS  Google Scholar 

  20. Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010;51(6):656–62.

    Article  PubMed  CAS  Google Scholar 

  21. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine. 2009;27(5):765–72.

    Article  PubMed  CAS  Google Scholar 

  22. Chan SH, Tan PTN, Han HH, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singap Med J. 2006;47(4):286–90.

    CAS  Google Scholar 

  23. Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000;19(6):628–36.

    Article  PubMed  CAS  Google Scholar 

  24. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18(20):2075–82.

    Article  PubMed  Google Scholar 

  25. Weston WM, Friedland LR, Wu X, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. Vaccine. 2012;30(9):1721–8.

    Article  PubMed  CAS  Google Scholar 

  26. Schmitt HJ, von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275(1):37–41.

    Article  PubMed  CAS  Google Scholar 

  27. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129(5):695–701.

    Article  PubMed  CAS  Google Scholar 

  28. Weston W, Messier M, Friedland LR, et al. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine. 2011;29(47):8483–6.

    Article  PubMed  CAS  Google Scholar 

  29. McIntyre PB, Turnbull FM, Egan AM, et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23(3):380–5.

    Article  PubMed  CAS  Google Scholar 

  30. Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis. 2007;44(10):1271–7.

    Article  PubMed  CAS  Google Scholar 

  31. Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39(2):179–85.

    Article  PubMed  CAS  Google Scholar 

  32. Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination (result summary of study no. 113055). Brentford, UK: GlaxoSmithKline; 2011.

  33. McIntyre PB, Burgess MA, Egan A. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine. 2009;27(7):1062–6.

    Article  PubMed  CAS  Google Scholar 

  34. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Ped Infect Dis J. 2009;28(2):152–3.

    Article  Google Scholar 

  35. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555–63.

    Article  PubMed  CAS  Google Scholar 

  36. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315–21.

    Article  PubMed  Google Scholar 

  37. Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149(5):603–10.

    Article  PubMed  CAS  Google Scholar 

  38. Bose A, Dubey AP, Gandhi D, et al. Safety and reactogenicity of a low-dose diphtheria-tetanus-acellular pertussis vaccine (Boostrix™) in pre-school Indian children. Indian Pediatr. 2007;44(6):421–4.

    PubMed  CAS  Google Scholar 

  39. Vergara R, Tregnaghi M, Ussher J, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164(6):377–82.

    Article  PubMed  Google Scholar 

  40. Weston WM, Friedland LR, Wu X. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29(5):1017–22.

    Article  PubMed  CAS  Google Scholar 

  41. Weston WM, Chandrashekar V, Friedland LR, et al. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009;5(12):858–66.

    PubMed  CAS  Google Scholar 

  42. Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30(12):e225–34.

    Article  PubMed  Google Scholar 

  43. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States Health Maintenance Organization. Pediatr Infect Dis J. 2010;29(7):613–7.

    Article  PubMed  Google Scholar 

  44. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27(32):4257–62.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs 2012; 72 (13):1765–91 [4]. The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Lesley J. Scott & Paul L. McCormack

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Additional information

The manuscript was reviewed by: H.O. Hallander, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden; E. Leuridan, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, WHO Collaborating Centre for Control and Prevention of Infectious Diseases, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; P. Van Damme, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, WHO Collaborating Centre for Control and Prevention of Infectious Diseases, University of Antwerp, Antwerp, Belgium.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., McCormack, P.L. Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®). BioDrugs 27, 75–81 (2013). https://doi.org/10.1007/s40259-012-0009-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-012-0009-y

Keywords

Search

Navigation